Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03233334
Other study ID # CKMR-1702
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2017
Est. completion date January 31, 2019

Study information

Verified date July 2019
Source Allina Health System
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Purpose Project intervention is an 8-session progressive structure that was developed based on theoretical and scientific evidence from psychology and occupational therapy. The goal of the intervention is to provide participants with information, tools, and support that help them move towards reclaiming a sense of self-grounded purpose in daily life. The study will use a convenience sample of women with breast cancer to evaluate the feasibility of the Purpose Project intervention in terms of demand/acceptability, implementation, and limited-efficacy testing. Findings will be used to inform a later study to evaluate the efficacy of the Purpose Project intervention.


Recruitment information / eligibility

Status Completed
Enrollment 15
Est. completion date January 31, 2019
Est. primary completion date August 1, 2018
Accepts healthy volunteers No
Gender Female
Age group 25 Years to 74 Years
Eligibility Inclusion Criteria:

1. Between 25 and 74 years of age

2. Completed chemotherapy and/or radiation treatment for Stage 1, 2, or 3 breast cancer up to 5 years prior to study enrollment

3. English speaking

4. Graduated from high school

5. Able to see, hear, speak (with or without assistive devices)

6. Able to provide own transportation to sessions

7. Willing and able to commit to attend all 8 intervention sessions, 2 testing sessions, and the one-to-one interview that occurs after completing the 8 intervention sessions.

Exclusion Criteria:

1. Stage 4 breast cancer or any other stage 4 cancer

2. Actively receiving chemotherapy or radiation treatments for cancer. (However, patients may be on Herceptin and/or endocrine treatment and participate in the study.)

3. History of neurologic disorder (such as stroke or brain injury) with residual impairments that likely interfere with learning

4. Any medical condition (physical or mental health) that interferes with the performance of everyday activities and roles.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Purpose Project
The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.

Locations

Country Name City State
United States Abbott Northwestern Hospital Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Allina Health System

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in psychological well-being Using the Psychological Scales of Wellbeing questionnaire (Ryff, 1989; Ryff, & Keyes, 1995), psychological wellbeing pre- and post- intervention will be tracked. Will be administered at Week 0 (pre-testing) and at Week 12 (session 8).
Secondary Recruitment Number of prospective participants approached by clinicians and number of self-referred prospective participants who contact PI or Study Coordinator with inquiries about the study Up to 1 month after IRB approval
Secondary Time of pre-testing session Actual length (in minutes) of pre-testing session. Duration of pre-testing session (approximately 2 hours) at week 0 to week 1
Secondary Time of testing session Actual length (in minutes) of testing session. Each week from week 2 through week 8, approximately 2.5 hours at each session
Secondary Time of post-testing session Actual length (in minutes) of testing session. Duration of session 8 (at week 12), approximately 2 hours
Secondary Homework completion Whether or not homework was attempted Each week from week 2 through week 8
Secondary Intervention fidelity Which key intervention elements were provided during a given session Each week from week 2 through week 8
Secondary Change in Meaning in life Meaning in Life Questionnaire (Steger et al., 2006): A 10-item questionnaire designed to measure 2 dimensions of meaning in life: Presence of Meaning (how much respondents feel their lives have meaning) and Search for Meaning (how much respondents strive to find meaning and understanding in their lives). At week 0 and at week 12
Secondary Change in Satisfaction with Participation in Discretionary Social Activities Satisfaction with Participation in Discretionary Social Activities (Hahn et al., 2010): Self-report questionnaires in which participants rated their level of satisfaction (1-5 scale) with social roles (14 items) and discretionary activities (12 items). At week 0 and at week 12
Secondary Engagement in Meaningful Activities Engagement in Meaningful Activities Survey (Eakman, 2010):A 12-item self-report questionnaire designed to measure the extent to which a person experiences meaningfulness in his/her daily life activities. At week 0 and at week 12
Secondary Purpose Status and Expectations A 2-question self-report developed by the study team to better understand what participants' hope to gain during the study and perceived changes. At Week 12
Secondary Participant Experience of Purpose Project Participant experience of purpose project as measured by self-report questionnaire and post-intervention interview. At week 12 and at week 14-20
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2